Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD

Sustained Remission of Relapsed Diffuse Large B-cell Lymphoma After Safe Administration of CD19-directed CAR T-cells in a Patient With Chronic Intestinal and Pulmonal GvHD

Bibliographic Details
Main Authors:	Nadine Kutsch, Philipp Gödel, Conrad-Amadeus Voltin, Carsten Kobe, Michael Hallek, Christof Scheid, Peter Borchmann, Udo Holtick
Format:	Article
Language:	English
Published:	Wiley 2022-07-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000735

Similar Items

Burden and Needs of Patients with Severe GvHD from the Supportive and Palliative Care Perspective—A Literature Review
by: Freya Wenzel, et al.
Published: (2021-05-01)

Modulation of T-regulatory cells by small molecules: potential therapy for GvHD
by: Leuschner, U
Published: (2021)

Cellular Strategies for Separating GvHD from GvL in Haploidentical Transplantation
by: Mauro Di Ianni, et al.
Published: (2024-01-01)

Immunometabolic Therapeutic Targets of Graft-versus-Host Disease (GvHD)
by: Kudakwashe Mhandire, et al.
Published: (2021-10-01)

Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells
by: Haroon Shaikh, et al.
Published: (2022-11-01)

In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
by: Kottaridis, P, et al.
Published: (2001)

Accumulation of T-cell-suppressive PD-L1high extracellular vesicles is associated with GvHD and might impact GvL efficacy
by: Regina Jitschin, et al.
Published: (2023-03-01)

Campath 1 H "in the bag" is an effective method of GvHD prevention in allogeneic stem cell transplantation.
by: Potter, M, et al.
Published: (2000)

Hematologic Rescue of CAR T-cell–mediated Prolonged Pancytopenia Using Autologous Peripheral Blood Hematopoietic Stem Cells in a Lymphoma Patient
by: Philipp Gödel, et al.
Published: (2021-03-01)

Extracorporeal photopheresis as an immunomodulatory treatment modality for chronic GvHD and the importance of emerging biomarkers
by: Ines Bojanic, et al.
Published: (2023-02-01)

Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation
by: Hemn Mohammadpour, et al.
Published: (2023-03-01)

The Relationship between STR-PCR Chimerism Analysis and Chronic GvHD following Hematopoietic Stem Cell Transplantation
by: Seyed Asadollah Mousavi, et al.
Published: (2016-12-01)

HSCT with Mismatched Unrelated Donors (MMUD): A Comparison of Different Platforms for GvHD Prophylaxis
by: Massimo Berger, et al.
Published: (2022-02-01)

Off-the-shelf third-party HSC-engineered iNKT cells for ameliorating GvHD while preserving GvL effect in the treatment of blood cancers
by: Yan-Ruide Li, et al.
Published: (2022-09-01)

In marrow aplasia reduced-intensity conditioning and T-cell depletion of cytokine mobilised stem cells provides good engraftment without GvHD
by: Novitzky, N, et al.
Published: (2006)

Effective Extracorporeal Photopheresis of Patients with Transplantation Induced Acute Intestinal GvHD and Bronchiolitis Obliterans Syndrome
by: Robin Reschke, et al.
Published: (2022-08-01)

Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD
by: Weijia Zhao, et al.
Published: (2023-08-01)

IL-10 mRNA Engineered MSCs Demonstrate Enhanced Anti-Inflammation in an Acute GvHD Model
by: Cuiping Zhang, et al.
Published: (2021-11-01)

Ewing sarcoma partial regression without GvHD by chondromodulin-I/HLA-A*02:01-specific allorestricted T cell receptor transgenic T cells
by: Uwe Thiel, et al.
Published: (2017-05-01)

Addition of cyclosporin post transplantation decreases GvHD without enhancing the adverse effect of T-cell depletion with CAMPATH-1H "in the bag": The cape town experience
by: Novitzky, N, et al.
Published: (2003)

Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement
by: Nikolett Lupsa, et al.
Published: (2022-02-01)

FDG-PET Imaging for Hodgkin and Diffuse Large B-Cell Lymphoma—An Updated Overview
by: Conrad-Amadeus Voltin, et al.
Published: (2020-03-01)

Posttransplant de novo DSA and NDSA affect GvHD, OS, and DFS after haplo-HSCT in patients without pre-existing HLA antibodies of hematological malignancies
by: Lan Wang, et al.
Published: (2022-12-01)

Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
by: Conrad-Amadeus Voltin, et al.
Published: (2023-01-01)

P008: Impact of bone marrow involvement on early PET response and progression-free survival in the HD18 trial for patients with advanced-stage Hodgkin lymphoma
by: Conrad-Amadeus Voltin, et al.
Published: (2022-10-01)

P024: Predictive Value of Baseline Metabolic Tumor Volume in Early-Stage Favorable Hodgkin Lymphoma – Data from the Prospective, Multicenter Phase III HD16 Trial
by: Lutz Van Heek, et al.
Published: (2022-10-01)

NIH consensus chronic GvHD following T-replete reduced-intensity conditioning sibling allograft usually develops within a year, causes prolonged morbidity but low mortality and is influenced by prophylactic methotrexate dose
by: Medd, P, et al.
Published: (2010)

Rearrangement of T Cell genome architecture regulates GVHD
by: Yaping Sun, et al.
Published: (2022-09-01)

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT
by: P. Borchmann, et al.
Published: (2022-06-01)

Developing a supportive and palliative care intervention for patients with allogeneic stem cell transplantation: protocol of a multicentre mixed-methods study (allo-PaS)
by: Martin Hellmich, et al.
Published: (2023-08-01)

Influences on PET Quantification and Interpretation
by: Julian M. M. Rogasch, et al.
Published: (2022-02-01)

REDUCED INCIDENCE OF GVHD IN RECIPIENTS OF T-CELL DEPLETED MARROW
by: Apperley, J, et al.
Published: (1986)

Longitudinal proteomics study of serum changes after allogeneic HSCT reveals potential markers of metabolic complications related to aGvHD
by: Sing Ying Wong, et al.
Published: (2022-08-01)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
by: Shabnam Shokouhi, et al.
Published: (2015-09-01)

Einladung Ausserordentliche GV 2006
by: Swiss Chemical Society
Published: (2006-08-01)

Einladung Ausserordentliche GV 2006
by: Swiss Chemical Society
Published: (2006-08-01)

The thymus in GVHD pathophysiology.
by: Krenger, W, et al.
Published: (2008)

The immunopathology of thymic GVHD.
by: Krenger, W, et al.
Published: (2008)

T020: Interim PET-guided treatment of early-stage nodular lymphocyte-predominant Hodgkin lymphoma: a subgroup analysis of the GHSG HD16 and HD17 studies
by: Dennis A. Eichenauer, et al.
Published: (2022-10-01)

Cáncer de pulmón
by: Carlos Manzano, et al.
Published: (2023-07-01)